Market Place
Sourcing Support
EU Okays Alexion’s Koselugo For Adults With Neurofibromatosis
31 Oct 2025 //
INDPHARMAPOST
Destiny-Lung06 Trial Begins: Enhertu Phase 3 For 1St-Line HER2
30 Oct 2025 //
BUSINESSWIRE
Takeda Drops Az-Partnered Neurological Program After Ph. 2 Fail
30 Oct 2025 //
FIERCE BIOTECH
Biogen Seeks To Stand Out In Lupus With New Anti-CD40L Data
28 Oct 2025 //
BIOSPACE
Novavax offloads HQ lease to AstraZeneca in $60M deal
23 Oct 2025 //
FIERCE PHARMA
Imfinzi Reduces Death Risk By 32% In High-Risk Bladder Cancer
22 Oct 2025 //
INDPHARMAPOST
Novartis Sues Az`s Alexion Over `Misleading` Ultomiris Marketing
22 Oct 2025 //
FIERCE PHARMA
CHMP Recommends Saphnelo Self-Admin Approval For Lupus In EU
21 Oct 2025 //
PHARMIWEB
ESMO: The ADC `Rollercoaster` Rides On With Next-Gen Meds
21 Oct 2025 //
FIERCE BIOTECH
AstraZeneca`s Datroway Extends Survival in Breast Cancer
20 Oct 2025 //
REUTERS
Tezspire Approved for Chronic Rhinosinusitis with Nasal Polyps
20 Oct 2025 //
PRESS RELEASE
AZ Faces FDA Challenge As Imfinzi-Lynparza Miss Survival Goal
19 Oct 2025 //
FIERCE PHARMA
ESMO: Datroway Data Edge Out Trodelvy In First TROP2 Face-Off
19 Oct 2025 //
FIERCE PHARMA
Enhertu+THP Yields 67% pCR in High-Risk HER2+ Breast Cancer
18 Oct 2025 //
BUSINESSWIRE
Enhertu Cuts Recurrence or Death Risk by 53% in Ph3 Breast Trial
18 Oct 2025 //
BUSINESSWIRE
ENHERTU® Preceded By THP Yields 67% Pathologic Response
18 Oct 2025 //
BUSINESSWIRE
Enhertu Cuts Recurrence Risk By 53% In High-Risk Her2 Cancer
18 Oct 2025 //
BUSINESSWIRE
ESMO: Enhertu Wields 2-Fisted Power In Early Breast Cancer
18 Oct 2025 //
FIERCE PHARMA
ESMO: Astrazeneca Data `Validate` Focus On In-House Adcs
18 Oct 2025 //
FIERCE BIOTECH
Imfinzi Cuts Death Risk 22% in Early Gastric Cancer Ph3
17 Oct 2025 //
BUSINESSWIRE
Imfinzi Cuts Recurrence Risk 32% in NMIBC Ph3 POTOMAC
17 Oct 2025 //
BUSINESSWIRE
Datroway`s Rilvegostomig Show Promise Result in Urothelial Cancer
17 Oct 2025 //
BUSINESSWIRE
Az`s Imfinzi Looks Set Up For Another Bladder Cancer Expansion
17 Oct 2025 //
FIERCE PHARMA
Astrazeneca Pens Fresh IBD Collab With Immunai Worth $85M
17 Oct 2025 //
FIERCE BIOTECH
Astrazeneca India To Launch Sodium Zirconium Cyclosilicate Powder
17 Oct 2025 //
INDPHARMAPOST
Personalis Reveals Latest Results From Landmark Lung Cancer Trial
16 Oct 2025 //
BUSINESSWIRE
AZ To Spend $445M To Boost Production Of Lokelma At Texas Plant
15 Oct 2025 //
FIERCE PHARMA
Ona Pharma Appoints Dr. Antoine Yver To Drive ADC Programs
14 Oct 2025 //
PHARMIWEB
Astrazeneca Advances Cancer Care Redefinition With Initial Data
13 Oct 2025 //
BUSINESSWIRE
Astrazeneca To Present Cancer Trial Breakthrough At ESMO 2025
13 Oct 2025 //
INDPHARMAPOST
Astrazeneca To Lower Cost Of Medicines For American Patients
12 Oct 2025 //
INDPHARMAPOST
AZ Breaks Ground On $4.5B API Production Facility In Virginia
11 Oct 2025 //
FIERCE PHARMA
Astrazeneca Strikes DTC Deal With Trump Administration
10 Oct 2025 //
BIOSPACE
Astrazeneca To Formalize MFN Agreement With Trump: MSNBC
10 Oct 2025 //
FIERCE PHARMA
Astrazeneca: Building A Transparent Pipeline From The Ground Up
10 Oct 2025 //
FIERCE BIOTECH
Algen Biotech Partners Astrazeneca For AI Drug Discovery
09 Oct 2025 //
PR NEWSWIRE
Turbine Collaborate With Astrazeneca To Rationalize ADC Discovery
09 Oct 2025 //
PR NEWSWIRE
AstraZeneca`s Baxdrostat Meets Goal in High Blood Pressure StudyS
08 Oct 2025 //
REUTERS
Baxdrostat Meets Primary Endpoint In BAX24 Phase 3 Trial
07 Oct 2025 //
BUSINESSWIRE
AstraZeneca & Daiichi`s Datroway Boosts survival in Breast Cancer
06 Oct 2025 //
REUTERS
AstraZeneca inks $555M Gene-Editing Tech Deal with Algen
06 Oct 2025 //
REUTERS
Astrazeneca Pharma India Gets CDSCO Approval For Trastuzumab
04 Oct 2025 //
INDPHARMAPOST
Big Pharma`s `Brexit` Draws Call For Anticompetition Probe
03 Oct 2025 //
FIERCE PHARMA
Thermo Fisher, AstraZeneca BioVentureHub Form R&D Partnership
01 Oct 2025 //
BUSINESSWIRE
UK`s Credibility Challenge Impedes Pharma Industry Retention
01 Oct 2025 //
BIOSPACE
ENHERTU THP Combo BLA Accepted for High-Risk HER2+ Breast Cancer
01 Oct 2025 //
BUSINESSWIRE
ENHERTU Shows iDFS Benefit in High-Risk Early Breast Cancer
29 Sep 2025 //
BUSINESSWIRE
Az, Daiichi`s Enhertu Notches Another Win In Early Breast Cancer
29 Sep 2025 //
FIERCE PHARMA
Astrazeneca Plots NYSE Listing Amid Uk Industry Pullback
29 Sep 2025 //
FIERCE PHARMA
Novartis, Boehringer Debut DTC Programs With Reduced Drug Prices
29 Sep 2025 //
FIERCE PHARMA
Factor Bio Files Complaint Against Cellectis & AstraZeneca
26 Sep 2025 //
PR NEWSWIRE
Astrazeneca Debuts DTC Service With Discounted Farxiga, Airsupra
26 Sep 2025 //
FIERCE PHARMA
Astrazeneca Makes Last-Chance IRA Appeal To Us Supreme Court
25 Sep 2025 //
FIERCE PHARMA
Direct-To-Patient Programs Are On The Rise At Pharmas: Survey
25 Sep 2025 //
FIERCE PHARMA
ENHERTU + Pertuzumab Gets US Priority Review In 1L HER2+ Cancer
24 Sep 2025 //
BUSINESSWIRE
Burning Rock`s Oncoguide Oncoscreen Plus CDX Approved In Japan
24 Sep 2025 //
GLOBENEWSWIRE
SOPHiA, AstraZeneca Expand Cancer Detection Collaboration
22 Sep 2025 //
PR NEWSWIRE
JCR Pharma & Alexion Hit Milestone in Neurodegenerative Program
19 Sep 2025 //
PHARMAWEB
AstraZeneca`s Saphnelo Triumphs in Phase 3 as Self-Injectable
18 Sep 2025 //
PRESS RELEASE
Airsupra US: Significant Risk Reduction in Mild Asthma Patients
18 Sep 2025 //
BUSINESSWIRE
